S'abonner

EUS-guided drainage of peripancreatic fluid collections and necrosis by using a novel lumen-apposing stent: a large retrospective, multicenter U.S. experience (with videos) - 09/01/16

Doi : 10.1016/j.gie.2015.10.020 
Ali A. Siddiqui, MD 1, , Douglas G. Adler, MD 2, , Jose Nieto, MD 3, Janak N. Shah, MD 4, Kenneth F. Binmoeller, MD 4, Steve Kane, BS 4, Linda Yan, MD 1, Sobia N. Laique, MD 1, Thomas Kowalski, MD 1, David E. Loren, MD 1, Linda Jo Taylor, BS 2, Satish Munigala, MD, MPH 5, Yasser M. Bhat, MD 4
1 Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 
2 Division of Gastroenterology and Hepatology, University of Utah Hospital, Salt Lake City, Utah 
3 Borland-Groover Clinic, Jacksonville, Florida 
4 Interventional Endoscopy Services (IES), California Pacific Medical Center, San Francisco, California 
5 Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, Missouri, USA 

Reprint requests: Douglas G. Adler, MD, Division of Gastroenterology and Hepatology, University of Utah Hospital, 30 N 1900 E, 4R118, Salt Lake City, UT 84132.Division of Gastroenterology and Hepatology, University of Utah Hospital30 N 1900 E, 4R118Salt Lake CityUT 84132
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 09 January 2016
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Background and Aims

EUS-guided drainage of peripancreatic fluid collection (PFC) (pancreatic pseudocyst [PP] or walled-off necrosis [WON]) by using a novel lumen-apposing, fully covered, self-expandable metal stent (LAMS) has been promising, but few of these data are from the United States. The aim of this study was to evaluate clinical outcomes and safety of EUS-guided drainage of pancreatic pseudocysts and WON by using the LAMS.

Methods

We conducted a multicenter, retrospective study on 82 patients with symptomatic PFC who underwent EUS-guided drainage by using the LAMS at 4 U.S. tertiary care centers. Outcomes evaluated included successful placement of the LAMS, the number of patients in whom complete resolution of PPs or WON was achieved, the number of procedures performed per patient to achieve PFC resolution, and adverse events.

Results

The mean size of the PFC was 11.8 cm. LAMSs were successfully placed in 80 patients (97.5%). Twelve patients had PP and 68 had WON. The median stent in-dwelling time was 2 months (range 1-3 months). Endoscopic debridement with the LAMS in WON was performed in 54 patients. The patency of the stent was maintained in 98.7% of the patients (77/78). There was spontaneous dislodgment of 2 LAMSs. Successful endoscopic therapy by using the LAMS was successful in 12 of 12 patients (100%) with PP compared with 60 of 68 patients (88.2%) with WON. All stents were endoscopically removed from all patients after peripancreatic fluid collection (PFC) resolution. There was 1 PFC recurrence during the 3-month median follow-up period. Procedure-related adverse events occurred in 8 patients (9.8%), and included stent maldeployment (n = 2), and self-limited bleeding (n = 6). In 1 patient with stent maldeployment gastric perforation developed, and the patient underwent surgical repair.

Conclusion

EUS-guided drainage of PFCs by using the novel LAMS has high technical and long-term success rates. Due to its ease of use, the LAMSs may simplify and streamline EUS-guided management of PFCs, particularly for the endoscopic debridement of WON, and may help in its widespread adoption as an alternative to surgery.

Le texte complet de cet article est disponible en PDF.

Abbreviations : FCSEM, LAMS, PFC, PP, WON


Plan


 DISCLOSURE: Dr Binmoeller is the founder and CMO of Xlumena Inc (equity ownership). All other authors disclosed no financial relationships relevant to this publication. This study was funded entirely by existing intramural funds and salary support from the respective institutions.
 If you would like to chat with an author of this article, you may contact Dr Adler at Douglas.Adler@hsc.utah.edu.


© 2016  American Society for Gastrointestinal Endoscopy. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.